Low serum level of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption

Tohoku Journal of Experimental Medicine

Volumn 218, Issue 3, 2009, Pages 201-205

  Aonuma, Hiroshi ^a   Miyakoshi, Naohisa ^a   Hongo, Michio ^a   Kasukawa, Yuji ^a   Shimada, Yoichi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alendronate; Bone alkaline phosphatase (BAP); Bone mineral density; Cross linked N telopeptide of type 1 collagen (NTx); Undercarboxylated osteocalcin (ucCOC)

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; OSTEOCALCIN; VITAMIN K GROUP; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; TREATMENT DURATION; BLOOD; CHEMOLUMINESCENCE; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION; DRUG EFFECT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; METABOLISM;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BONE DENSITY; BONE RESORPTION; CHEMILUMINESCENT MEASUREMENTS; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOENZYME TECHNIQUES; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 68849102110     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.218.201     Document Type: Article

References (26)

1. Binkley, N.C., Krueger, D.C., Kawahara, T.N., Engelke, J.A., Chappell, R.J. & Suttie, J.W. (2002) A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation. Am. J. Clin. Nutr., 76, 1055-1060.
2. Black, D.M., Cummings, S.R., Karpf, D.B., Cauley, J.A., Thompson, D.E., Nevitt, M.C., Bauer, D.C., Genant, H.K., Haskell, W.L., Marcus, R., Ott, S.M., Torner, J.C., Quandt, S.A., Reiss, T.F. & Ensrud, K.E. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 348, 1535-1541.
3. Black, D.M., Thompson, D.E., Bauer, D.C., Ensrud, K., Musliner, T., Hochberg, M.C., Nevitt, M.C., Suryawanshi, S. & Cummings, S.R.; FIT Research Group. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J. Clin. Endocrinol. Metab., 85, 4118-4124.
4. Boivin, G.Y., Chavassieux, P.M., Santora, A.C., Yates, J. & Meunier, P.J. (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone, 27, 687-694.
5. Borah, B., Dufresne, T.E., Ritman, E.L., Jorgensen, S.M., Liu, S., Chmielewski, P.A., Phipps, R.J., Zhou, X., Sibonga, J.D. & Turner, R.T. (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone, 39, 345-352.
6. Braga de Castro Machado, A., Hannon, R. & Eastell, R. (1999) Monitoring alendronate therapy for osteoporosis. J. Bone Miner. Res., 14, 602-608.
7. Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P. & Guyatt, G.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev., 23, 508-516.
8. Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A., Palermo, L., Prineas, R., Rubin, S.M., Scott, J.C., Vogt, T., Wallace, R., Yates, A.J. & LaCroix, A.Z. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 280, 2077-2082.
9. Durchschlag, E., Paschalis, E.P., Zoehrer, R., Roschger, P., Fratzl, P., Recker, R., Phipps, R. & Klaushofer, K. (2006) Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J. Bone Miner. Res., 21, 1581-1590.
10. Greenspan, S.L., Parker, R.A., Ferguson, L., Rosen, H.N., Maitland-Ramsey, L. & Karpf, D.B. (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J. Bone Miner. Res., 13, 1431-1438.
11. Hauschka, P.V., Lian, J.B., Cole, D.E. & Gundberg, C.M. (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol. Rev., 69, 990-1047.
12. Hirao, M., Hashimoto, J., Ando, W., Ono, T. & Yoshikawa, H. (2008) Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J. Bone Miner. Metab., 26, 260-264.
13. Kaneki, M., Hodges, S.J., Hosoi, T., Fujiwara, S., Lyons, A., Crean, S.J., Ishida, N., Nakagawa, M., Takechi, M., Sano, Y., Mizuno, Y., Hoshino, S., Miyao, M., Inoue, S., Horiki, K., Shiraki, M., Ouchi, Y. & Orimo, H. (2001) Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition, 17, 315-321. Erratum in: (2006) Nutrition, 22, 1075.
14. Liberman, U.A., Weiss, S.R., Bröll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-Portales, J., Downs, R.W. Jr., Dequeker, J. & Favus, M. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med., 333, 1437-1443.
15. Liu, G. & Peacock, M. (1998) Age-related changes in serum undercarboxylated osteocalcin and its relationships with bone density, bone quality, and hip fracture. Calcif. Tissue Int., 62, 286-289.
16. Miyakoshi, N., Shimada, Y., Ando, S., Minato, T. & Itoi, E. (2006) Effects of alfacalcidol alone or in combination with elcatonin on incidence of osteoporotic vertebral fractures in postmenopausal women with spondylosis. J. Bone Miner. Metab., 24, 491-497.
17. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA, 285, 785-795.
18. Recker, R., Masarachia, P., Santora, A., Howard, T., Chavassieux, P., Arlot, M., Rodan, G., Wehren, L. & Kimmel, D. (2005) Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr. Med. Res. Opin., 21, 185-194. Erratum in: (2005) Curr. Med. Res. Opin., 21, 324.
19. Saito, M., Fujii, K. & Marumo, K. (2006) Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif. Tissue Int., 79, 160-168.
20. Schnitzler, C.M. (1993) Bone quality: a determinant for certain risk factors for bone fragility. Calcif. Tissue Int., 53 Suppl 1, S27-31.
21. Shiraki, M., Kushida, K., Fukunaga, M., Kishimoto, H., Kaneda, K., Minaguchi, H., Inoue, T., Tomita, A., Nagata, Y., Nakashima, M. & Orimo, H. (1998) A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr. J., 45, 191-201.
22. Sogabe, N., Tsugawa, N., Maruyama, R., Kamao, M., Kinoshita, H., Okano, T., Hosoi, T. & Goseki-Sone, M. (2007) Nutritional effects of gamma-glutamyl carboxylase gene polymorphism on the correlation between the vitamin K status and gamma-carboxylation of osteocalcin in young males. J. Nutr. Sci. Vitaminol. (Tokyo), 53, 419-425.
23. Sokoll, L.J. & Sadowski, J.A. (1996) Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. Am. J. Clin. Nutr., 63, 566-573.
24. Szulc, P., Chapuy, M.C., Meunier, P.J. & Delmas, P.D. (1996) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone, 18, 487-488.
25. Tsugawa, N., Shiraki, M., Suhara, Y., Kamao, M., Tanaka, K. & Okano, T. (2006) Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gamma-carboxylation of osteocalcin. Am. J. Clin. Nutr., 83, 380-386.
26. Vergnaud, P., Garnero, P., Meunier, P.J., Bréart, G., Kamihagi, K. & Delmas, P.D. (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J. Clin. Endocrinol. Metab., 82, 719-724.